Skip to Content

Press Releases

Date Title Additional Format
Oct 31, 2019
Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis
- Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations - LONDON --(BUSINESS WIRE)--Oct.
Oct 30, 2019
Vertex Reports Third-Quarter 2019 Financial Results
- Product revenues of $950 million , a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - BOSTON --(BUSINESS WIRE)--Oct. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial
Oct 24, 2019
Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines
-Eligible patients in England will have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor)- LONDON --(BUSINESS WIRE)--Oct. 24, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with
Oct 21, 2019
Vertex to Announce Third-Quarter 2019 Financial Results on October 30
BOSTON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
Oct 21, 2019
ADDING MULTIMEDIA FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved
Oct 21, 2019
FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved
Oct 21, 2019
Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)
LONDON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ®
Oct 19, 2019
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia
LONDON --(BUSINESS WIRE)--Oct. 19, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO ® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who
Oct 18, 2019
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age
- If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - LONDON --(BUSINESS WIRE)--Oct. 18, 2019-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for
Oct 01, 2019
Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer
  BOSTON --(BUSINESS WIRE)--Oct. 1, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic , M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs. Dr.
Sep 30, 2019
Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
  -Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs-     -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments-     BOSTON & DURHAM, N.C. --(BUSINESS WIRE)--Sep.
Sep 12, 2019
Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)
Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor LONDON --(BUSINESS WIRE)--Sep. 12, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis
Sep 10, 2019
Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11
BOSTON --(BUSINESS WIRE)--Sep. 10, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET . The audio portion of management’s remarks can be accessed
Sep 03, 2019
Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes
-Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- BOSTON & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.
Aug 20, 2019
FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment
-FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020 - -Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in
Jul 31, 2019
Vertex Reports Second-Quarter 2019 Financial Results
- Product revenues of $940 million , a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3.6 to $3.7 billion - - Company advancing programs in 5 additional diseases beyond cystic fibrosis - BOSTON --(BUSINESS WIRE)--Jul.
Jul 25, 2019
Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer
BOSTON --(BUSINESS WIRE)--Jul. 25, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden , M.D., Ph.D, into the role of Executive Chairman of the
Jul 22, 2019
Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis
-Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations- BOSTON --(BUSINESS WIRE)--Jul. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:
Jul 17, 2019
Vertex to Announce Second-Quarter 2019 Financial Results on July 31
BOSTON --(BUSINESS WIRE)--Jul. 17, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Jun 21, 2019
FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene
-SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range- BOSTON --(BUSINESS WIRE)--Jun.
Displaying 141 - 160 of 744